Rotarix: PMS Dr. Shailesh MEHTA GSK IAPCOI meeting Mumbai, 24 th Dec 2011
Not a single case of Intussusception was reported in this study
PSUR Data of Rotarix India
India Yr of Launch 2008 till Dec death 13 cases of intussusception ( of this 1 case of blood in stools, no intussusception on USG )
India Sr No. Loc Ref NoAge ( Months )Gender Date Received by GSKEvent Text (uncoded)OCEANS Case ID 1 IN/2008/001315Male18-Sep-08ILEOCOLICINTUSSCEPTIONB A 2 IN/2009/00027N/A 13-Mar-09INTERCEPTION (INTESTINAL BLOCK)B A 3 IN/2009/000384Male3-Apr-09INTUSSUSCEPTIONB A 4 IN/2009/000555Male21-Apr-09INTUSSUSPTIONB A 5 IN/2009/000587Male30-Apr-09INTUSUSCCPTIONB A 6 IN/2009/001237Male1-Oct-09INTUSSUSCEPTIONB A 7 IN/2010/000113Female1-Feb-10INTUSSUSCEPTIONB A 8 IN/2010/000415Male18-May-10, USG ABDOMEN - BOWEL WALL EDEMA SUGGESTIVE OF ?AUTOREDUCTION OF INTUSSUSCEPTION.B A 9 IN/2010/001944Male29-Oct-10 ILEOCAECAL- COLIC INTUSSUSN REQD RESECTN ANASTOMOSIS FOR GANGRENOUS BOWEL.B A 10 IN/2010/001967Male2-Nov-10 BLOOD IN STOOLS (OVER 24 HRS ) 7-8 HRS AFTER BEING ADMINISTERED THE 2ND DOSE OF ROTARIX 6 MONTHS OF AGE.USG ABD DONE - NO INTUSSUSPTN.B A 11 IN/2011/000834Male14-Mar-11 OPERATED FOR REDUCTION OF INTUSSUCEPTIONB A 12 IN/2011/001367Male16-May-11 DIAGNOSED INTUSSUSCEPTION ON USG ABD. SURGICAL REDUCN DONEB A 13 IN/2011/001683Female2-Jul-11 31/2 MTH OLD FCH WAS ADMINISTERED RTX 1ST DOSE AT AM ON 1ST JUL"11. BABY died within 12 hrs of vaccination.B A 14 IN/2011/001705Female7-Jul-11 5 MONTH OLD BABY DEVELOPED INTUSSUSCEPTION 2 MONTHS AFTER THE 2ND DOSE OF ROTARIX VACCINE.B A
PSUR Data of Rotarix Global
PSUR Data: Worldwide (July 2004-July 2011) International Birth Date: 12 July 2004 (Mexico) 1. Data Lock Points: 12 July 2004 to 11 January cases of intussusception have been reported 2. Data Lock Points: 12 January July cases of intussusception after vaccination have been reported 3. Data Lock Points: 12 July 2006 –11 January cases of intussusception were received 4. Data Lock Points: 12 January 2007 – 11 July cases of intussusception have been received. 5. Data Lock Points: 12 July 2007 – 11 January cases of intussusception (IS) have been received during the period of this report. 6. Data Lock Points: 12 January 2008 – 11 July cases of intussusception (IS) have been received during the period of this report. 7. Data Lock Points: 12 July 2008 – 11 Jan cases of intussusception (IS) have been received during the period of this report. 8. Data Lock Points: 12 Jan 2009 – 11 Jul cases of intussusception (IS) have been received during the period of this report. 9. Data Lock Points: 12 Jul 2009 – 11 Jan cases of intussusception (IS) have been received during the period of this report. 10. Data Lock Points: 12 Jan 2010 – 11 Jul cases of intussusception (IS) have been received during the period of this report 11. Data Lock Points: 12 Jul 2010 – 11 Jul cases of intussusception (IS) have been received during the period of this report
Thanks you
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Rotarix™ and Rotateq® active surveillance in Australia Active surveillance for IS Two active surveillance mechanisms: Hospital-based case findings (the Paediatric Enhanced Disease Surveillance [PAEDS] hospital-based network) Monthly reports from paediatricians (the Australian Paediatric Surveillance Unit [APSU]) No overall increase in IS following rotavirus vaccination Evidence suggestive of an elevated risk within 21 days following the first dose only IS cases following Dose 1 in infants 1 to ≤3 months Rotarix ™RotaTeq® 1–7 days relative risk [RR]3.5 (95%CI: 0.7, 10.1)5.3 (95%CI: 1.1, 15.4) 1–21 days RR1.5 (95%CI: 0.4, 3.9)3.5 (95%CI: 1.3, 7.6) Buttery et al. Vaccine 2011, doi: /j.vaccine [in press] Rotarix is a trademark of the GlaxoSmithKline group of companies RotaTeq is a registered trademark of Merck & Co., Inc.
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Mexican PASS study on IS with Rotarix™: interim analysis (January 2008 – December 2009) Methods Prospective, hospital-based active surveillance for definite IS Conducted in 66 hospitals (Instituto Mexicano del Seguro Social) across Mexico, covering a birth cohort of approximately 500,000 infants Assessment of temporal association between vaccination and onset of IS by self-controlled case-series analysis Primary interim safety objective was considered met if the upper limit of the 99%CI of the relative incidence of IS within 31 days of vaccination was <4.33 for Dose 1 and <2.18 for Dose 2, corresponding to an additional risk of 2/10,000 based on experience with a previous RV vaccine (RotaShield™) Velazquez et al. Acta Pædiatrica 2010: 99(Suppl. 462): 47–120, PP106 (special issue: Abstracts from the 2 nd Excellence in Paediatrics conference, 2 – 4 Dec 2010, London, UK) Rotarix is a trademark of the GlaxoSmithKline group of companies RotaShield is a trademark of Wyeth
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Mexican PASS study on IS with Rotarix™: interim analysis (January 2008 – December 2009) Results 461 episodes of IS reported in 459 subjects Clustering of IS cases within 7 days of vaccination observed post-Dose 1, but not post-Dose 2 Dose Risk period (days) IS relative incidence99% CI 10– –3.080P = – –1.873P = Velazquez et al. Acta Pædiatrica 2010: 99(Suppl. 462): 47–120, PP106 (special issue: Abstracts from the 2 nd Excellence in Paediatrics conference, 2 – 4 Dec 2010, London, UK) Rotarix is a trademark of the GlaxoSmithKline group of companies
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Mexican PASS study on IS with Rotarix™: Summary on the interim analysis Based on these data, GSK concludes that the benefit/risk profile for Rotarix™ continues to be clinically acceptable As a risk minimisation measure, the current Rotarix™ prescribing information and patient leaflets alert HCP and parents to monitor vaccinated infants for signs and symptoms of IS Data have been shared with regulatory and supranational authorities around the world, including the EMA, the FDA, TGA, WHO and PAHO: USA label for Rotarix™ was the first to be updated on September 17, The corresponding label update is under review by the other Authorities 1. [accessed Sept 29 th 2010] Rotarix is a trademark of the GlaxoSmithKline group of companies
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Rotarix™ efficacy against severe RVGE (Rota-037, Africa) *Rotarix™ N=2,974 n (%) Placebo N=1,443 n (%) VE % (95% CI) p value Severe RVGE56 (1.9)70 (4.9)61.2 (44.0–73.2)<0.001 Infants randomly assigned into three groups (1:1:1) to receive two doses of Rotarix™ at 10 and 14 weeks of age; three doses of Rotarix™ at 6, 10, and 14 weeks of age; or three doses of placebo to test the hypothesis that infants may require three doses of vaccine in this setting HIV positive subjects not excluded Efficacy calculated from 2 weeks post-last dose of Rotarix™ /placebo until 1 year of age: according-to-protocol (ATP) cohort for efficacy *Pooled (2 doses and 3 doses) vaccine cohort N = number of subjects included in each group; n = number of subjects reporting at least one event in each group n/N (%) = percentage of subjects reporting at least one event; VE (%) = vaccine efficacy (conditional method); CI = confidence intervals Severity of RVGE was assessed using the 20-point Vesikari scale (severe RVGE ≥11) p value = two-sided Fisher’s exact test Madhi SA et al. N Engl J Med 2010; 362: 289–98 Rotarix is a trademark of the GlaxoSmithKline group of companies
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Burden of RV potentially prevented in Africa (Rota-037) Ruiz-Palacios GM et al. N Engl J Med 2006; 354: 11–22; Madhi SA et al. N Engl J Med 2010; 362: 289 – 98 Severe RVGE episodes prevented per 100 children per year – comparison with Latin America (and Finland) study (Rota-023) Severe RVGE episodes per 100 infant-years Placebo Vaccine
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals OPV co-ad (six countries) severe RVGE 4 1st year FU: 81.6% (54.4–93.5) Three countries severe RVGE 5–7 1st FU: 100% (72.2–100) 2nd FU: 96.1% (85.1–99.5) 3rd FU: 100% (67.5–100.0) Two countries severe RVGE 8 1st FU: 61.2% (44.0–73.2) Six countries severe RVGE 3 1st FU: 95.8% (89.6–98.7) 2nd FU: 90.4% (85.1–94.1) 11 countries severe RVGE 1,2 1st FU: 84.7% (71.7–92.4) 2nd year FU: 80.5% (71.3–87.1) Rotarix™ global efficacy against severe RVGE Central and South America Europe South East Asia Africa References in speaker notes Co-ad, co-administration; FU, follow-up Rotarix is a trademark of the GlaxoSmithKline group of companies
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals Rotarix™ protects against a broad range of RV types: integrated analysis of randomised control trials Any RVGESevere RVGE (≥11 Vesikari score) Vaccine efficacy (%, 95% CI) De Vos B et al. Pediat Infect Dis J 2009; 28: 261–6. Figures reproduced with permission from Lippincott Williams & Wilkins. CI, confidence intervals Meta-analysis of five studies: Rota-004 (Finland), 006 (Brazil, Mexico, Venezuela), 007 (Singapore), 023 (Latin America – 11 countries), 036 (Europe – 6 countries) G1P[8]G3P[8]G4P[8]G9P[8]G2P[4] G1P[8]G3P[8]G4P[8]G9P[8]G2P[4] 82.6% 87.7% 87.4% 90.2% 84.9% 60.6% 93.4% 83.8% 81.0% 71.4% Rotarix is a trademark of the GlaxoSmithKline group of companies
Global Expert Academy on Rotavirus ROT Sponsored by GlaxoSmithKline Biologicals G1G2G3G4G8G9G12 SourceVE [95% CI] against severe RVGE 1-year follow-up Ruiz-Palacios et al Latin America 90.8 [70–98] 45.4 [<0–86] *86.9 [63–97] *86.9 [63–97] - *86.9 [63–97] - Neuzil et al Africa 64.1 [30–82] 79.2 [9–97] 83.8 [10–98] [17–85] [<0–78] Vesikari et al Europe 96.4 [86–100] 74.7 [<0–100] 100 [45–100] 100 [65–100] [78–99] - SourceVE [95% CI] against severe RVGE 2-year follow-up Linhares et al Latin America 82.7 [64–93] 43.8 [<0–88] **82.2 [70–90] **82.2 [70–90] - **82.2 [70–90] - Phua et al Asia 100 [81–100] 100 [<0–100] 94.5 [65–100] [44–100] - Vesikari et al Europe 96.4 [90–99] 85.5 [24–99] 93.7 [53–100] 95.4 [68–100] [72–93] - *Pooled data for G3, G4 and G9. **Pooled data for P[8] non-G1 (G3, G4, G9) References in speaker notes. VE, vaccine efficacy; CI, confidence intervals Rotarix™ protects against a broad range of RV types Rotarix is a trademark of the GlaxoSmithKline group of companies